Projects

Request appointment	Request data sheet	I Like it

× Close
The depelopment of high soluble fiber and niacine for controlling the hyperlipidemia

Request appointment	Request data sheet	I Like it

× Close
Present invention was developed in PRO/BIONICS, it is an artificial arm used in aiding handicapped people in their rehabilitation. It incorporates three modules: arm, forearm and elbow which are assembled depending on the needs of each patient. It´s designed under ergonomic, functional and cosmetics parameters. It´s manufactured with light, resistant and economic materials. Arm control is accomplished by an electronic-brain interface that reads the muscular contractions over patient´s skin at his trunnion so that he can carry out the arm´s movements controlling speed and force. It is provided with a cosmetic glove made of latex/silicon and a rechargeable I-Li battery.

Request appointment	Request data sheet	I Like it

× Close
Recently, the World Economic Forum has ranked Mexico as the 60th place on the Global Competitiveness Index. It has droped ...

Request appointment	Request data sheet	I Like it

× Close
Dengue is the most important arbovirus affecting humans in many countries that are located in the tropical and subtropical areas. Dengue is caused by any of the four serotypes of dengue virus transmitted through the Aedes aegypti vector mosquito bite. All serotypes circulate simultaneously in the country. Mexico has 26 states with active dengue transmission (629 municipalities and 43 million people at risk). Insect biological control is a viable alternative that has been used successfully in other countries. The bacteria most commonly used in insect biological control is undoubtedly Bacillus thuringiensis (Bt). Bt is a Gram-positive bacteria that produces crystalline inclusions during the sporulation phase. At the National Autonomous University of Mexico Institute of Biotechnology, a Bt-based formulation that is toxic to Ae. aegypti mosquito larvae was developed, its features are that it has a prolonged duration (at least two months), resists water exchange, non-toxic to living organisms, except for mosquito larvae. This formulation was field evaluated in two Mexican rural regions and the required drug and toxicity studies to obtain marketing permits are being made. Type of technology developed: BT spores from native strains production process technology. Formulation of a biopesticide against dengue product technology. Current Status of Intellectual Property: Patent application in process Offering institution: Company incubated at UNAM facilities. Technology Progress: Fermentation process is well controlled, it is necessary to scale. Tests are made, but further research is needed on product presentation. Offered technology opportunities: The control of dengue in the world is imperative. The current technology used for this purpose is highly polluting and alternatives must be discovered. Sought institution characteristics: Company and/or investor to provide capital for development completion.

Request appointment	Request data sheet	I Like it

× Close
BACKGROUND Global BioTherapeutics (GBT) is an R&D biotech company at the forefront of biotechnology. Founded in 2009 by MDs, biologists, biochemists and biotech-engineers, GBT focuses on developing novel molecules for the inhibition of angiogenesis. GBT contemplates the use of two platforms for the application of its molecules: 1) through conventional biotechnology, in which the patient receives the recombinant protein; 2) through the use of gene therapy in which the patient receives the DNA coding the therapeutic protein and the patient itself synthesizes the protein. R&D GBT has an R&D pipeline of more than 15 molecules in different stages of development.- GBTs molecules are engineered to posses two properties that separate them from the angiogenic inhibitors so far described: 1) an increased anti angiogenic profile and 2) optimized bio-availability.- In addition, GBT has described a novel method to deliver recombinant gene encoding vectors to the liver in which sustained expression is observed for 1 year.- Such method will revolutionize gene therapy at a global level.- Global BioTherapeutics (GBT) in collaboration with an eminent group of north american engineers and doctors has developed novel devices to deliver recombinant vectors to the liver in a clinical scenario. This novel method will not only be of use for the application of GBTs molecules, it will also impact those pathologies that can be reversed by prolonged gene expression of a soluble proteins. TECHNOLOGY HIGHLIGHTS - Novel anti angiogenic molecules.- - A state of the art gene therapy platform with sustained gene expression for 1 yr without immune-suppression, fancy molecular constructs or sophisticated viral vectors - Strong and growing markets - Solid IP strategy POTENTIAL MARKETS -Hemophilia -Alpha-1-antitrypsin deficiency -Rheumatoid Arthritis -Cancer - Med Tech market -Any pathology that can be reversed by prolonged gene expression of a soluble proteins. LEGAL & INTELLECTUAL PROPERTY GBT is legally represented in Mexico by SAI- Law & Economy (www.sai.com.mx) GBT has built, and continues to build, a strong picket fence for intellectual property protection and is represented by Levine Bagade Han in the San Francisco Bay Area. GBT’s patent portfolio includes offensive and defensive patent filings related to: 1) Novel therapeutic anti-angiogenic molecules 2) The method of delivery of the viral vector 3) The medical devices required to effect the novel delivery method Gustavo Cabrera, MD, PhD- Has been involved in the field of gene of therapy since 1994.- Has worked for academic institutions as PI and consultant for pharmaceutical firms for the past 7 years in Mexico City, Mexico.- Founded Global BioTherapeutics (GBT) in 2009 and serves as CEO.- GBT’s R&D focuses on two elements of gene therapy, novel ways to deliver therapeutic genes to target organs and in the development of novel molecules.- GBT will file its first patents in 2010. Blanca Segura, M.Sc. PhD- A molecular biologist specialized in epigenetics, Dr. Segura has been involved in the field of gene therapy since 2005, co-founded GBT in 2009 and serves as Director of R&D. Leafar Perez-Romano , M . en C. A biochemist with seven years of experience in molecular biology, immunochemistry and gene therapy.- Has labored in both private and governmental institutions developing methods and molecules for therapeutical purposes. Having vast experience in quality control and regulatory affairs, M. en C.Perez- Romano serves as GBT’s Director for Regulatory Affairs. Daniel Burnett, MD- A Bioengineer by training, Dr. Burnett worked for the FDA and has 8 issued and over 40 pending patents. Over the last five years he has founded four venture- backed medical device ventures- BAROnova, Novashunt, Velomedix and EMKinetics- and helped raise over $50M for these ventures. Dr. Burnett has also worked as a General Partner at a medical device focused venture firm and received his MD and MBA from Duke University. John Rabkin, MD- An active liver transplant surgeon at California Pacific Medical Center. Dr. Rabkin serves as a reviewer for the Annals of Surgery, a liaison to the American Society of Transplant Surgeons and Vice Chairman of the Organ Procurement Organizations Committee. He is active in research relating to liver transplants and has medical device development experience with several companies in the San Francisco Bay Area. Krystof Bankiewicz, MD, PhD- Because of his extensive experience at supervising multi-investigator translational programs, Krystof is the Kinetics Foundation Chair in Translational Research at UCSF. He is the inventor of 8 patents and has developed novel gene-therapy treatments for neurological disorders. He is currently running a Phase-1 clinical trial for AAV-hAADC gene therapy and has resolved technical and scientific issues with respect to filing an IND application with the FDA.-

Request appointment	Request data sheet	I Like it

× Close
Peptic ulcer, atrophic gastritis and stomach cancer are the most important gastric diseases in Mexico and most of them could be related to infection by H. pylori strains of high virulence. Vacuolating cytotoxin (VacA) and CagA protein are virulence factors that are expressed only in pathogenic strains, which have been isolated from patients with severe gastric diseases. With potential detection of specific antibodies that recognize these proteins we would predict whether a patient is at risk of developing serious illness. There are other virulence factors required for colonization and survival in the human stomach and are therefore expressed by all strains. These include: urease, catalase, peroxiredoxin (AhpC) and various adhesins. The antibody detection that recognizes these antigens would allow us to ponder the bacterial load that is colonizing the gastric epithelium. Commercial diagnose methods that are currently sold in our country for the detection of H. pylori infection may lead to false negatives, because the antigens used are not from strains circulating in our country. In this project we propose to develop a test for early diagnosis of patients infected with H. pylori virulent strains based on the use of specific antigens such as VacA, CagA, urease B, catalase and Napa, which will prevent nonspecific reactions so far obtained by using complex antigen mixtures. This will make it possible to identify infected patients at risk of developing a severe gastric disease through the detection of antibody serum (IgG, IgA and IgM) based on the immunoblot technique and using various antigens including major virulence factors associated with pathogenic strains in Mexico. In addition, the strip will follow up on people who are being treated with antibiotics, to assess the effectiveness of treatment or to detect a possible re-infection. Type of technology developed: Product technology Current Status of Intellectual Property: No current result protection. Offering institution: Public Health National Institute. Technology Progress: Early development stages. Offered technology opportunities: The H. pylori gastric diseases diagnose are growing. The opportunity to diagnose strains affecting the Mexican population is an opportunity for the local market. Sought institution characteristics: Pharmaceutical industries with experience in the development of diagnose tests.

Request appointment	Request data sheet	I Like it

× Close
A drug from a vegetable extract of a Mexican plant has been developed, wich is provided with the necessary methodology for its controlled agro-industrial production. Also it has the technological methodology to prepare a vegetable extract that can be standardized in its active ingredient responsible for antimycotic activity, ensuring in this way the production of a shampoo. The product has been already tested in patients who, after a one month treatment, the drandruff vanished, without secondary effects after its employment. The extract from which the shampoo is made, contains a formula containing the necessary amount of the compounds with anti-dandruff activity. We have the technology to produce a standardized and high quality plant extract from the vegetable material, to quantify active ingredients in the extract, as well as the technique to produce an anti-dandruff shampoo on a semi-industrial scale. The technology has been protected by a patent Application field: Cosmetic industry Type of technology developed: Process and product technology Current Status of Intellectual Property: Patent granted in Mexico Offering institution: IMSS (Instituto Mexicano del Seguro Social) Southern Biomedical Research Center Technology Progress: High. The active ingredients have been identified. We have analytical methods for active compound quantification, and the therapeutic efficiency has been proved. We also have the technology to grow plants from which extracts are obtained.. Opportunities of the offered technology: High potential market. Sought institution characteristics: A company with experience in health or cosmetic fields, interested in licensing or technology transfer.

Request appointment	Request data sheet	I Like it

× Close
Industrial development of a pharmaceutical formulation to treat onychomycosis. The phytomedicine is developed from the extracts of the Ageratina pichinchensis plant species, standardized in its active compound content. The drug has shown high clinical effectiveness in the treatment of mild to moderate onychomycosis (by double-blind, randomized and controlled clinical studies in samples larger than 100 patients), the pharmacological effect has been attributed to a series of active compounds fully identified and quantified in the species. The phytomedicine worked in previously multi-treated patients, so it can be considered as an option for a mycosis treatment that is resistant to existing treatments in the market. Application field: Cosmetic Industry, dermatological industry. Type of technology developed: Process and product technology Current Status of Intellectual Property: Patent granted in Mexico Offering institution: IMSS Southern Biomedical Research Center Technology Progress: High. The plants active ingredients have been identified, the therapeutic efficiency of the product has been clinically proven, and certain advantages of the product over the competition can be observed. Offered technology opportunities: The anti-mycotic sector is an area of great potential because of its rapid growth. Sought institution characteristics: Pharmaceutical Company interested in acquiring the technology license.

Request appointment	Request data sheet	I Like it

× Close
Industrial development of a pharmaceutical formulation for anxiety treatment. This is a phytomedicine made with the extracts of a plant species, standardized in its active compounds content. The drug is characterized by having shown (in a double-blind clinical trial in 152 patients with generalized anxiety) a significant anxiolytic effect as effective as that produced by lorazepam (one of the most powerful anxiolytics), which starts from the first week of treatment, but without evidence of significant side effects. The pharmacological effect has been attributed to a series of active compounds in the plant, called galphiminas. The action mechanism identified in addition to being new is promising as it is specific to neuronal receptors linked to anxiety. Type of technology developed: Product and process technology related to the anxiolytic. Current Status of Intellectual Property: Technology protection through national patent pending. Offering institution: IMSS Southern Biomedical Research Center Technology Progress: High. The effectiveness of the product has demonstrated through clinical trials. The active ingredients have been identified. Offered technology opportunities: Anxiety treatment is increasing. The product has shown no adverse effects. Sought institution characteristics: Established company in the pharmaceutical industry.

Request appointment	Request data sheet	I Like it

× Close
Galphimia glauca Cav. is a plant used in Mexican Traditional Medicine. Different studies have demonstrated that the crude extract from the plant’s aerial parts possess an anxiolytic effect. Galphimine B (GB, a nor,secotriterpene), is the main active principle, with an innovating and selective action mechanism. Several pharmacological, chemical, toxicological and biotechnological studies supported the development of a phytopharmaceutical containing the standardized extract of G. glauca. This product was evaluated clinically by means of a double blind clinical trial in order to compare with lorazepam (1 mg x day) therapeutic effectiveness, safety, and tolerability on patients with Generalized Anxiety Disorder (GAD). After 4 weeks treatment, the phytopharmaceutical showed important anxiolytic effectiveness, very similar to that produced with lorazepam. Nevertheless, concerning side effects the phytopharmaceutical evidenced considerably higher tolerability than lorazepam.

Request appointment	Request data sheet	I Like it

× Close

Request appointment	Request data sheet	I Like it

× Close
.

Request appointment	Request data sheet	I Like it

× Close
Infection by Candida glabrata is the second greatest cause of human infection of candidas (after C. albicans) and has been reported in 17-23% in blood infections. Among hospital infections, a 51% mortality rate has been reported in these blood infections. (Vermitsky 2008; Pfaller 2002) Moreover, it has been the principal cause of candida infections in diabetic patients (61%) and among the elderly (51%). For these reasons, infection by C. glabrata has become a serious problem in the field of public health. Standard treatment for candidiasis is with azoles (fluconazol, voriconazol, etc.). Nevertheless, C. glabrata may already have or may develop resistance to these antifungals. Therefore, a timely diagnosis should be made to modify treatments and avoid complications. Currently, diagnosis using cultures and biochemical tests take up to approximately 4-12 days, with effectiveness of between 65 y 85%, during which time the risk of infection increases. TECHNOLOGY: In IPICYT, we have developed and filed a patent application for a new technology that permits identification of the presence of C. glabrata in a more effective way than the existing options on the market for the following reasons: � The procedure takes only 2 hours on urine samples and 4 hours on blood samples. � Accuracy of 100% in determining positive proof of C. glabrata was achieved in a study of more than 250 clinical samples. � The genetic regions protected by the patent are unique to this species and that their uniqueness has been tested on mixtures of fungi and bacteria. � The diagnosis can be made by different methods of PCR, so that the tests can be performed in practically any hospital diagnostic unit. BENEFITS FOR USERS: Quick diagnosis, 100% effectiveness and reduction of costs. � Facilitates and expedites treatment for this type of infection. � Facilitates control of hospital in-patient infections. � The mortality rate due to this pathogen will be reduced. � It requires PCR equipment and techniques which are already widely utilized in clinical laboratories. � Doctors have confidence in the results of this type of testing. MARKET: Clinical laboratories and hospitals throughout the world. DEVELOPMENT: Ready to begin clinical trials and to initiate procedures for FDA approval (COFEPRIS, etc.) INTELLECTUAL PROPERTY: Patent application filed in march 2009. PCT filed in march 2010. It is available for national filing procedures. Available for licensing. OPPORTUNITY: IPICYT seeks licensing for this technology with companies that can perform clinical tests and establish its worldwide commercialization.

Request appointment	Request data sheet	I Like it

× Close
The determination of biological structures has promoted a revolution in the comprehension of the life processes. Knowing the structure of macromolecules has projected the understanding of the processes and mechanism of living beings. Suffice to mention that the knowledge of the structure of AND, obtained by X-ray diffraction in the sixteen’s allowed to establish the central dogma from genetics, this generate the development of the biotechnology and originated unimaginable applications in those days. The search of the active site of proteins, the formation, interaction, and macromolecule-macromolecule (protein-protein, protein-polysaccharide, protein-carbohydrate, protein-lipid, protein-nucleic acid, and protein-drug) complexes formation, is focused primarily towards the systematic studies about drug design that have direct social benefits. All those processes direct and indirectly have application in the biopharmacy, food industry, biomedicine and biotechnology. In México there are various laboratories that work in the obtaining of the structure of macromolecules; however, despite the great effort achieved into the different institutions, has not be possible increase and expand this area. The fact of do not possess specialized and updated equipment for the structural elucidation has kept a sustained development, with the respective delay on the scientific competence to world level. So, the creation of the Laboratorio Nacional de Estructura de Macromoléculas (LANEM) in a great chance to impulse immediately this area, taking advantage of the existing infrastructure, and putting it to the disposition of all the research groups in Mexico. LANEM accounts with two units, the Nuclear Magnetic Resonance (NMR) unit, and the X-Ray Difraction (XR) unit, the first located in the NMR Laboratory of CIQ-UAEM, and the second, in the Laboratorio Universitario de Estructura de Proteinas of IQ-UNAM. The interest for the determination of macromolecular structures has been increased in our country during the last years, so, this discipline is in development in different institutions from the country. Nevertheless the actual scientific developments require counting with specialized and updated equipment of major sensitivity. The determination of the tridimensional structure of macromolecules with immediate applications in the explanation of reactivity phenomena, macromolecule-macromolecule, and macromolecule-ligand interactions has a clear social benefit. MISSION: To support those research groups or companies in Mexico which require obtaining the tridimensional structure of macromolecules with potential application on biomedicine, biotechnology, medicinal chemistry, polymers and pharmacy. This National Laboratory has two advanced units: a) Nuclear Magnetic Resonance Unit, located at the Chemical Research Center from UAEM. b) X-Ray Difraction Unit, located at the Chemistry Institute from UNAM. The establishment of the LANEM results strategically important for the South-Center area of Mexico, where there are located a great amount of research centers and institutes, as well as industrial companies (chemical, pharmaceutical, food, polymers, agrochemical, etc.), which there are waiting to use the service of resolution of the tridimensional structure of their molecules. This will greatly contribute to the consolidation of these research groups and academic corps from this region. It is totally justified the establishment of the LANEM in Cuernavaca city, which is considered the knowledge capitol, since it has a number of researchers interested in the development of this area, as will propitiate the developing of multidisciplinary and frontier investigations of international level. In addition, the LANEM will provide service to other institutions, giving place to technological developments. Even more, been this National Laboratory THE FIRST IN ITS TYPE IN LATIN AMERICA, will be possible the obtain collaboration agreements with Latin America Institutions. OTHER BENEFITS: a) Highly specialized in Nuclear Magnetic Resonance and X-Ray techniques human resources development. b) Incidence in at least ten national Ph. D. programs in areas such as chemistry, biomedical sciences, pharmacy, biochemistry and health sciences. c) Chance to increase the interchange agreements with national or foreign institutions. d) Organize international meetings in the area of the structure of macromolecules. e) Foundation of the research area on structure of macromolecules, THE FIRST IN THE COUNTRY. f) Acquisition of high tech NMR and X-Ray equipment for the resolution of the structure of macromolecules. g) The LANEM will be a REFERENCE LABORATORY, so shall be applications from a number of Scientifics from Mexico and Latin America to do research and training stances with the NMR and X-Ray equipment. APPLICATIONS The obtaining of the structure of macromolecules such as proteins, enzymes, DNA, RNA, polypeptides, polysaccharides, polymers, etc., for medical, biomedical, pharmacy, food research. Possibility to perform metabolomic profiles through the quantification of metabolites of interest from biological samples such as: a) Metabolomic profiles of different brain regions, b) Quantification of the capsaiscin content in chili peppers, c) Fragance content in flower extracts, d) Quantification of bioactive natural products in medicinal plants, etc. Solid state analysis of membranes linked to proteins; this area is of interest for academic and industrial research, principally, the pharmaceutical industry. People interested in develop this area is located in the chemistry and biochemistry departments. Determination of purity and impurities. The people interested in this area are located in the quality control department of the general chemistry industry. Metabolomic studies of biofluids such as urine, saliva, plasma, sap, vegetable exudates, resins, essential oils, etc. IMPACT 1. Production and application of new knowledge about the understanding of chemical, biological, and biochemical phenomena. 2. Development of frontier research projects. 3. National and International collaborations 4. Multidisciplinary investigation. 5. Human resources development highly specialized on the structural elucidation of macromolecules. 6. Human resources development focused with a multidisciplinary vision. 7. Development and consolidation of a research network in the area of macromolecules. 8. Scientific publications and patents of high impact, book editions and anthologies. 9. Available databases for the scientific community. 10. New products of medicinal, biotechnological, chemical and industrial interest. AVAILABLE INFRASTRUCTURE NMR spectrometer VARIAN GEMINI at 200MHz NMR spectrometer VARIAN GEMINI at 400MHz NMR spectrometer VARIAN UNITY at 400MHz NMR spectrometer VARIAN INOVA at 500MHz X-Ray spectrometer for powders with area detector, BRUKER-AXS X-Ray diffractometer of monocrystal with area detector, BRUKER X-Ray generator with rotary anode and fosforescent plate detector, RAXISII-RIGAKU High resolution mass spectrometer with FAB and electro spray techniques. JEOL JMS-700 Mass spectrometer MALDI-TOF, OMNIFLEX-BRUKER X-Ray diffractometer with area generator and area detector (new). NMR spectrometer VARIAN GEMINI at 700 MHz with cryogenic probe (new). The equipment configurations are suitable to perform the structural determination of macromolecules and allow complementing the range of possibilities of structural elucidation available until now. In addition, the LANEM possess two of the more advanced equipments in their type in the country.

Request appointment	Request data sheet	I Like it

× Close
Breast cancer is the neoplasm with the highest incidence and mortality in women worldwide. In Mexico, a new case of breast cancer is diagnosed every 2 hours, with the Federal District the entity with the largest number of cases in the country. A problem in clinical breast cancer is the low response to initial chemotherapy and the high rate of recurrence of the disease. Consequently, the mortality reduction requires the development of molecular strategies to identify molecular predictors of recurrence and pathologic complete response which may contribute to the proper treatment of patients. Our group has focused on the search for microRNAs (miRNAs) and proteins differentially expressed in tumor biopsies of invasive breast cancer in Mexican patients in order to establish their potential as predictors of pathologic complete response and recurrence.

Request appointment	Request data sheet	I Like it

× Close
Methods for obtaining melanin by recombinant microbial strains that express tyrosinase. The processes are at pilot level production of melanin (eumelanin and pheomelanin). Melanin was produced with a volumetric productivity of 8.7 mg/ l-h and a final concentration of 0.29 g/l for pheomelanin (from L-tyrosine and L -Casein) and 94 mg/lh and to 6g / l for eumelanin (from L-tyrosine alone). Application field: Cosmetic industry (creams, suntan lotions, etc.) Type of technology developed: Process technology, pilot state Current Status of Intellectual Property: Patent application in process Offering institution: Biotechnology Institute UNAM Technology Progress: Early stages of development, pilot-level process (scaling to 100 lt) Offered technology opportunities: The cosmetic sector is the natural segment to apply this technology. Sought institution characteristics: Company in the cosmetic sector interested in acquiring technology license. scaling and testing stages completion required.

Request appointment	Request data sheet	I Like it

× Close
The development of a simple process to produce rotavirus proteins for triple layered rotavirus-like particles (tlRLP) production in Saccharomyces cerevisiae was evaluated in this work. The genes of the rotavirus structural proteins VP2, VP6 and VP7 were cloned in four Saccharomyces cerevisiae strains, using different plasmid and promoter combinations to express one, two or three proteins in the same cell.

Request appointment	Request data sheet	I Like it

× Close
Systematic analysis of biotechnology research projects about industrial property subjects. Search of potentially patentable inventions and performance of a patent and commercial viability analysis.

Request appointment	Request data sheet	I Like it

× Close
The new National Laboratory for Macromolecular Structure offer services to study macromolecules for potential applications in biomedical, biotechnology, medicinal chemistry and pharmacy. The laboratory has units of Nuclear Magnetic Resonance (NMR), X-ray crystallography and mass spectroscopy. This laboratory has a 700 MHz NMR magnet, the biggest in Mexico, which opens the door to a field of research in molecular biology previously nonexistent in the country, allowing the determination of: Three-dimensional structure in solution. NMR, along with X-ray diffraction, are the only two methodology that can be used to determine the molecular structure with high resolution. Interaction sites in molecules. NMR allows the study of interaction between bio-molecules. Duo to the simplicity it is the method of choice for screening of drugs. Dynamics. NMR is the only methodology that allows the study of the dynamics of macromolecules with atomic resolution on several time scales. Because proteins are not static entities, it is essential to study the movements to understand its functions.

Request appointment	Request data sheet	I Like it

× Close
Develop a communication platform that obtain basic clinical history of the user population of the country, that allows remote diagnosis, teleconsultation, reference and counter the population using medical services in the country. Promote the use of integrated high-technology telemedicine to increase the response capacity and organizational efficiency of health systems, creating an infrastructure for telemedicine systems. And the provision of remote medical services system integrating a clinical history online

Request appointment	Request data sheet	I Like it

× Close
Develop a communication platform that obtain basic clinical history of the user population of the country, that allows remote diagnosis, teleconsulting, reference and counter the population using medical services in the country. Promote the use of integrated high-technology telemedicine to increase the response capacity and organizational efficiency of health systems, creating an infrastructure for telemedicine systems. And the provision of remote medical services system integrating a clinical history online.

Request appointment	Request data sheet	I Like it

× Close

Request appointment	Request data sheet	I Like it

× Close
Vejovine is a peptide with antibiotic activity, which was isolated and characterized from the venom of a Mexican scorpion in the Vaejovis genre and was also chemically synthesized successfully. We have the complete primary structure. Vejovine, both native and synthetic, inhibits the growth of bacterial cultures such as Pseudomonas aeruginosa, Escherichia coli, Enterobacter cloacae and Klebsiella pneumonia, strains which have been isolated by the National Public Health Institute as highly resistant to traditional antibiotics. Also, we have additional data to generate possible modifications. Some pharmaceutical compositions for the implementation of the new peptide have been developed. The application is topical. We have the molecule chemical synthesis process. Application field: Pharmaceutical industry, antibiotics Type of technology developed: Product and process technology Current Status of Intellectual Property: National patent pending. Offering institution: Biotechnology Institute ���¢�¯�¿�½�¯�¿�½ UNAM Technology Progress: Early stages of development Offered technology opportunities: Therapeutic products derived from toxins isolated from venoms are very recent and have a very specific and fragmented market; therefore its value can be high. Sought institution characteristics: Company with experience in health industry, antibiotics. Interested in a licensing or technology transfer.

Request appointment	Request data sheet	I Like it

× Close
Recently, the World Economic Forum has ranked Mexico as the 60th place on the Global Competitiveness Inde

Request appointment	Request data sheet	I Like it

× Close

Request appointment	Request data sheet	I Like it

× Close

Request appointment	Request data sheet	I Like it

× Close

Request appointment	Request data sheet	I Like it

× Close
It is the development of an innovate system, semi-automated and sustainable in order to make a massive production of concentrates of different kind of micro alga either from the sea or from sweet waters, of an excellent nutritional quality, which will be alive food for aquatic organisms such as: mollusk, fish, crustacean, which are cultivated at laboratories of larva’s production and fattened farms. These concentrates are benefic for the growing of the aquatic organisms on their different stages, because of its variety of essential nutrients, that generates a speed increase of size, weight and also increase the nutritional value that the specie could contribute as food. The system has a re-circulation of the water for the cultivate, which make it a friendly to the environment, because it is only necessary to make a series of steps in order to use again the water. The system is composed by a bio-reactor conformed by a system of pipes with an automated lighting system, CO2 injection and tracking of the environment variables under the micro alga is cultivated.

Request appointment	Request data sheet	I Like it

× Close

Request appointment	Request data sheet	I Like it

× Close
The phytase market is estimated to be worth more than $200 million, growing at a rate of over 5% per year. The global market is mainly covered by two products: Natuphos, marketed by BASF Animal Nutrition and Ronozyme P, marketed by Roche Vitamins In. Both products are used in the feeding of pigs and chickens. Danisco Animal Nutrition entered to this market recently with a new generation of phytase Phyzyme XP (Thermo Protection Technology TPT) developed to increase the thermostability of this enzyme. Most of the commercial phytases are active in narrow acidic pH range and not resist high temperatures during feed processing. In this technological development, yeast strains overproducer of a new thermostable phytase with a beta-propeller structure designed by protein engineering were built. A laboratory scale (5 L) production bioprocess was developed and the potential application of the new enzyme was evaluated. A selected Pichia pastoris overproducer strain was able to produce up to 80,000 U/L phytase and secrete up 92% of the same. The new recombinant phytase (FTEII) has enzymatic activity in a broad pH range (2.5-9) and temperature (25 to 70�°C), shows a high residual activity (85 �± 2%) after 10 min of heat treatment at 80�°C, is more thermostable than commercial phytases evaluated, and is resistant to shrimp (Litopenaeus vannamei) and porcine trypsin. FTEII released 68 and 57% of the total phosphorus present in soy bean and a pea concentrated protein in treatments under neutral conditions at 40�°C respectively, two fold higher than treatments with commercial phytases. This new phytase may be useful as feed additive, since it can resist the temperatures used in the feed-pelleting process, and in the pretreatment of vegetable ingredients used in animal diets.

Request appointment	Request data sheet	I Like it

× Close
Technology based on a patent related to enzymes with chorismate mutase-prephenate dehydratase activity, insensitive to allosteric inhibition by phenylalanine and catalytically efficient. The technology includes the method for the L-phenylalanine production, the molecular vectors and the transformed bacterial strains. We also have a process for the phenylalanine production based on glucose fermentation with these strains. Yields obtained are up to 0.46g / L with a conversion efficiency up to 0.33g of L-phenylalanine / g glucose. Type of technology developed: Technology related with bacterial strains for enzyme production. Process technology for phenylalanine production. Current Status of Intellectual Property: Patent granted in Mexico. Offering institution: Biotechnology Institute- UNAM Technology Progress: Development on pilot level Opportunities of the offered technology: The use of phenylalanine is widely known as a sweetener. The process has high yield offer. Sought institution characteristics: Food industry company.

Request appointment	Request data sheet	I Like it

× Close
The assessment of the genetic variability in Jatropha curcas with molecular markers have been made using RAPD, ISSR and AFLP but were mostly confined to J.curcas accession available in India. The present study aims is the biodiversity analysis of local J curcas with high seed producing, high seed oil content, low or null toxicity, and ripening o drought tolerance

Request appointment	Request data sheet	I Like it

× Close
PHAs are natural polyesters synthesized by a large group of bacteria. These polymers are biocompatible thermoplastics used to produce biodegradable plastic products or to generate products with applications in medicine, such as sutures, prosthetic devices, engineering, tacks, staples, screws, bone plates, surgical mesh, stents, implants, artificial skin, orthopedic pins and others. PHB is the most common and best characterized PHAs polymer, which has the characteristic of being able to reach a high molecular weight (up to 4 million Daltons) that allows obtainment of highly specific materials used in biomedical applications. This technology is based on genetically modified bacteria for the efficient production of specialty PHB (biodegradable and biocompatible). PHB is used to produce nano and microfibers in electrospinned membrane generation that can be used as scaffolds for tissue engineering with competitive properties in the biomedical area. Type of technology developed: Process and product technology. Current Status of Intellectual Property: No current result protection. Offering institution: Biotechnology Institute UNAM Technology Progress: Very early development stages. Attained advances, at pilot plant level to obtain the biopolymer, are related to the fermentation process. Offered technology opportunities: PBH biomedical materials are in growth. The biomedical materials field is an area of high added value. Sought institution characteristics: Company in the equipment and/or medical supplies sector, interested in a strategic alliance to develop the missing stages in the technology. The PHB production technology has given rise to a university business incubation process

Request appointment	Request data sheet	I Like it

× Close
Promote the collective knowledge of scientific events with instruments that broadcast scientific, educational and biotechnological information such as the “INTERNATIONAL BIOTECHNOLOGY COLOR JOURNAL” that publishes the results of local, regional and international research on different areas where biotechnology is classified by color: 1.- TRANSPARENT: biotechnology and society, 2.- SILVER: economic development, biobusiness and marketing, 3.- IRIS: early stimulation education on health culture, nutrition, sports, arts, science, technology and society, 4.- RED: biotechnology applied to ensure health, production of diagnostic methods and medication, 5.- YELLOW: food biotechnology and production of nutritional improved food, 6.- BLUE: sea and coast applied biotechnology, 7.- DARK GREEN: geomicrobiology, agrobiotechnology, bioremediation and biofertilizers, 8.- GREENISH YELLOW: physiology, biochemistry and molecular biology used in biotechnology, 9.- LIME GREEN: development of renewable and sustainable energy such as bioenergetics, 10.- BROWN: biotechnology applied to arid and desert zones, 11.- BLACK: bioterrorism, biological war, biocrime, black antibiotechnology, 12.- PURPLE: patents, publications, inventions, industrial and intellectual property rights, 13.- WHITE: gene based bioindustry, 14.- GOLD: bioinformatics and nanobiotechnology, 15.- GRAY: classic fermentation and bioprocess technology=================== ===== 5.- Support the transfer of science and technology on the subject of education and biotechnology promoting a meeting of scientists, education and biotechnology, teachers and students in different levels of education: basic, middle superior, superior and postgraduate education, by carrying out the INTERNATIONAL CONGRESS ON COLOR BIOTECHNOLOGY, teaching conferences, plural debates, thematic summits, seminars and workshops, to award the prize for the DRAWING AND CHILD AND JUVENILE PAINTING AND COLOR BIOTECHNOLOGY as an early stimulation strategy on science and biotechnology.

Request appointment	Request data sheet	I Like it

× Close

Request appointment	Request data sheet	I Like it

× Close
The production of biodegradable plastics made from renewable raw materials is mandatory in modern times to minimize negative environmental impact caused by oil made plastics. In the bioplastic market, polylactates, better known as PLA, stand out for their thermoplastic properties that have the potential to displace oil plastic in the vast majority of applications, with the advantage that they can be obtained from renewable raw materials with environment friendly technology and the relevance of being fully biodegradable in a short period of time. Technology has been developed for obtaining D or optically pure L-lactate, which can be obtained from a wide variety of agro-industrial wastes such as whey or forestry waste, pulp, grasses, shrubs and basically all derived from lignocellulosic material. Once the lactate is subject to a chemical polymerization process, PLA is finally obtained. Type of technology developed: Process technology. We have developed a process for synthesizing PLA through fermentation processes. Pilot plant development. Current Status of Intellectual Property: Patent application in process Offering institution: Company in incubation process. Technology Progress: Necessary to scale the processes that have proven feasibility at pilot plant level. Offered technology opportunities: Biopolymers are gaining more ground on environmental issues, concerning raw material availability, but above all policy issues. Sought institution characteristics: Companies interested in strategic alliance. Prospective investor to assist in the development of missing elements (process scaling, testing of various raw materials).

Request appointment	Request data sheet	I Like it

× Close
Agroecological Biotech represents an alternative focus for the Agri Biotech development in our city, it is because besides it takes advantage of biotech on a wider way, to improve the living condictions of the rural area, it could be a strategic element in order to achieve a Sustainable Development of Mexico City, in which 59% of its territory is a rural area that nowadays confronts several problems related not only with the urban expansion but also with the spoilage of the living standards of its inhabitants. For that reason, I propose the cration of an Agroecological Program in Mexico City as an element that could contribute to solve those problems.

Request appointment	Request data sheet	I Like it

× Close
Company created based on a university technology for the production of peptides that are used in research and development. Type of technology developed: Product technology. Peptides are synthesized for research use. Current Status of Intellectual Property: No patent Offering institution: Company incubated at UNAM facilities. Technology Progress: Completely dominated technology. Offered technology opportunities: There is a great demand for antibodies used in investigation, and it is noted that in the case of Mexico (and even Latin America) domestic production may lead to import substitution. Sought institution characteristics: Company interested in an alliance. Institution willing to invest around 1.2 million USD.